DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Tokyo Big Sight

2017 年 11 月 12 日 9:30 上午 - 2017 年 11 月 14 日 5:30 下午

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

14th DIA Japan Annual Meeting 2017

[V5-S3] Approaches to Enhance Appropriate Communication on Pharmaceutical Product Information

Session Chair(s)

Mamoru  Narukawa, PhD, RPh

Mamoru Narukawa, PhD, RPh

Professor, Department of Clinical Medicine (Pharmaceutical Medicine)

Kitasato University School of Pharmacy , Japan

Yuko  Kojima, RPh

Yuko Kojima, RPh

Sr. Executive Director

Eli Lilly Japan K.K., Japan

It is highly important that pharmaceutical product information is appropriately provided by regulatory authorities and pharmaceutical companies, and utilized in the medical field. In the Japan annual meeting in 2016, we discussed issues arising from provision of pharmaceutical product information materials provided to healthcare professionals or patients, and handling of these issues. We have found that pharmaceutical product information is not necessarily fully utilized by the medical professionals: duplicate information is provided using various materials from the regulatory authorities and companies, necessary information for medical professionals is not provided, and the real intentions of the authors are not fully conveyed. In 2017, we will discuss approaches and future perspectives to enhance appropriate communication on pharmaceutical product information to medical professionals based on the previous discussion by summarizing the objectives and utilization methods of a wide range of information materials provided by the regulatory authorities and companies.

Speaker(s)

Tomoko  Tanita

Tomoko Tanita

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Risk Communication Promotion Division, Office of Safety I

Susumu  Wakabayashi

Susumu Wakabayashi

Kyorin University Hospital, Japan

Department of Pharmacy

Shinya  Takemoto, MSc

Shinya Takemoto, MSc

Chugai Pharmaceutical Co., Ltd., Japan

Group Manager, Safety Information Strategy Group, Risk Communication Department

Junichi  Nishino, MSc, RPh

Junichi Nishino, MSc, RPh

Otsuka Pharmaceutical Co., Ltd., Japan

Head, Regulatory Affairs Department

Toyotaka  Iguchi, MD, PhD

Toyotaka Iguchi, MD, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Director, Office of Safety II

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。